Alto Neuroscience, Inc. Proceeds from Stock Options Exercised
Alto Neuroscience, Inc. (ANRO) reported Proceeds from Stock Options Exercised of $81.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-12
- Alto Neuroscience, Inc. proceeds from stock options exercised for the quarter ending 2026-06-30 was $75.00K.
- Alto Neuroscience, Inc. proceeds from stock options exercised for the quarter ending 2026-03-31 was $6.00K, a 96.97% decline year-over-year.
- Alto Neuroscience, Inc. proceeds from stock options exercised for the quarter ending 2025-12-31 was $352.00K, a 618.37% increase year-over-year.
- Alto Neuroscience, Inc. proceeds from stock options exercised for the quarter ending 2025-09-30 was $153.00K, a 128.36% increase year-over-year.
- Alto Neuroscience, Inc. proceeds from stock options exercised for fiscal 2025 was $703.00K, a 275.94% increase from fiscal 2024.
- Alto Neuroscience, Inc. proceeds from stock options exercised for fiscal 2024 was $187.00K, a 3.31% increase from fiscal 2023.
- Alto Neuroscience, Inc. proceeds from stock options exercised for fiscal 2023 was $181.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $81.00K 10-Q · filed 2026-08-12 | $433.00K derived: sum of 3 quarters · filed 2026-08-12 | $586.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $6.00K 10-Q · filed 2026-05-13 | $358.00K derived: sum of 2 quarters · filed 2026-05-13 | $511.00K derived: sum of 3 quarters · filed 2026-05-13 | $511.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $505.00K derived: sum of 2 quarters · filed 2026-03-16 | $505.00K derived: sum of 3 quarters · filed 2026-08-12 | $703.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $153.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $153.00K derived: sum of 2 quarters · filed 2026-08-12 | $351.00K 10-Q · filed 2025-11-12 | $400.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $198.00K 10-Q · filed 2026-08-12 | $247.00K derived: sum of 3 quarters · filed 2026-08-12 | $314.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $198.00K 10-Q · filed 2026-05-13 | $247.00K derived: sum of 2 quarters · filed 2026-05-13 | $314.00K derived: sum of 3 quarters · filed 2026-05-13 | $375.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $116.00K derived: sum of 2 quarters · filed 2026-03-16 | $177.00K derived: sum of 3 quarters · filed 2026-03-16 | $187.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $67.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $128.00K derived: sum of 2 quarters · filed 2025-11-12 | $138.00K 10-Q · filed 2025-11-12 | $167.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $71.00K 10-Q · filed 2025-08-13 | $100.00K derived: sum of 3 quarters · filed 2025-08-13 | $209.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $10.00K 10-Q · filed 2025-05-14 | $39.00K derived: sum of 2 quarters · filed 2025-05-14 | $148.00K derived: sum of 3 quarters · filed 2025-05-14 | $191.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $138.00K derived: sum of 2 quarters · filed 2025-03-20 | $181.00K derived: sum of 3 quarters · filed 2025-03-20 | $181.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $152.00K derived: sum of 2 quarters · filed 2024-11-12 | $152.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $43.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |